Certara, Inc. (NASDAQ:CERT - Get Free Report) shares dropped 7.1% on Thursday . The company traded as low as $11.03 and last traded at $11.31. Approximately 243,047 shares changed hands during trading, a decline of 82% from the average daily volume of 1,364,727 shares. The stock had previously closed at $12.18.
Analyst Upgrades and Downgrades
Several research firms recently issued reports on CERT. JMP Securities reaffirmed a "market perform" rating on shares of Certara in a research note on Tuesday, May 6th. TD Cowen initiated coverage on Certara in a research report on Thursday, February 27th. They set a "buy" rating and a $16.00 target price on the stock. Stephens reissued an "overweight" rating and issued a $17.00 price target on shares of Certara in a report on Thursday, February 27th. Barclays upgraded Certara from an "equal weight" rating to an "overweight" rating and raised their price objective for the company from $11.00 to $14.00 in a research note on Thursday, May 8th. Finally, KeyCorp lifted their price objective on Certara from $15.00 to $18.00 and gave the stock an "overweight" rating in a report on Wednesday, April 16th. Three analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $15.67.
Check Out Our Latest Stock Analysis on Certara
Certara Stock Performance
The company has a debt-to-equity ratio of 0.28, a current ratio of 2.86 and a quick ratio of 2.86. The stock has a market capitalization of $1.79 billion, a P/E ratio of -55.05, a price-to-earnings-growth ratio of 9.29 and a beta of 1.44. The company has a fifty day moving average of $12.22 and a two-hundred day moving average of $11.88.
Certara (NASDAQ:CERT - Get Free Report) last issued its quarterly earnings results on Monday, May 5th. The company reported $0.14 earnings per share for the quarter, beating analysts' consensus estimates of $0.10 by $0.04. The business had revenue of $106.00 million during the quarter, compared to the consensus estimate of $104.44 million. Certara had a positive return on equity of 3.43% and a negative net margin of 8.34%. The business's quarterly revenue was up 9.7% on a year-over-year basis. During the same period in the previous year, the business earned $0.10 EPS. On average, equities analysts anticipate that Certara, Inc. will post 0.28 EPS for the current year.
Institutional Trading of Certara
A number of institutional investors and hedge funds have recently modified their holdings of the business. Jane Street Group LLC raised its stake in Certara by 17.1% during the first quarter. Jane Street Group LLC now owns 277,054 shares of the company's stock worth $2,743,000 after acquiring an additional 40,463 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Certara by 13.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 299,528 shares of the company's stock valued at $2,965,000 after acquiring an additional 35,954 shares during the period. Goldman Sachs Group Inc. raised its stake in shares of Certara by 65.6% during the first quarter. Goldman Sachs Group Inc. now owns 228,996 shares of the company's stock valued at $2,267,000 after purchasing an additional 90,724 shares in the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Certara in the 1st quarter worth approximately $297,000. Finally, Select Equity Group L.P. boosted its stake in Certara by 534.5% during the 1st quarter. Select Equity Group L.P. now owns 1,094,495 shares of the company's stock valued at $10,836,000 after purchasing an additional 922,007 shares in the last quarter. 73.96% of the stock is owned by institutional investors and hedge funds.
Certara Company Profile
(
Get Free Report)
Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.
Featured Stories
Before you consider Certara, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Certara wasn't on the list.
While Certara currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.